organization · Reporting owner
ATAI Life Sciences AG
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | 10% owner | September 26, 2024 | September 28, 2024 |
| IntelGenx Technologies Corp.IGXT · Entity 91524 | 10% owner | April 19, 2024 | May 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date September 26, 2024 · Filed September 28, 2024
Jointly reported with Atai Beckley N.V.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy ATAI Life Sciences AG | 6,905,774 |
Reported balance
After 2024-09-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-09-26 · Sale · Disposed 2,660,000 · Balance 6,905,774 F1: Securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the Ordinary Shares held of record by ATAI Life Sciences AG. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the Ordinary Shares held of record by ATAI Life Sciences AG.
IntelGenx Technologies Corp.
Report date April 19, 2024 · Filed May 03, 2024
Jointly reported with Atai Beckley N.V.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2026-02-01 | IndirectBy ATAI Life Sciences AG | Not disclosed |
Reported balance
After 2024-04-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-19 · Other · Acquired Not disclosed · Balance Not disclosed F1: On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable. F2: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable.
F2: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2024 Filed Sep 28, 2024 00:00 UTC | COMPASS Pathways plc CMPS · Entity 4567 | SaleOrdinary Shares | 2,660,000 | $6.05 | $16,093,000.00 |
DisclosureSEC source: 0001140361-24-042246 · form4.xml · nonDerivative · entry 1 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 6,905,774 F1 · ownership.nature: Securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the Ordinary Shares held of record by ATAI Life Sciences AG. Read SEC document |
| April 19, 2024 Filed May 3, 2024 16:05 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | OtherConvertible Notes · Derivative | Not disclosed | Not disclosed Strike: $0.19 | $1,000,000.00 |
DisclosureSEC source: 0000950170-24-052877 · ownership.xml · derivative · entry 1 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: Not disclosed Underlying: Common Stock · 5,405,405 shares Expires 2026-02-01 F1 · kind: On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable. F1 · price: On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable. F1 · derivative.underlying_shares: On April 19, 2024, pursuant to the Third Amended and Restated Loan Agreement, ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Any accrued interest outstanding under the loan may be converted into shares of Common Stock at the five day volume weighted average price of the shares, less the maximum permitted discount under certain applicable rules, ending on the day that is the second business day before the day the interest becomes due and payable. F2 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | OtherWarrant (Right to Buy) · Derivative | 4,000,000 | Not disclosed Strike: $0.17 | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 6 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2027-03-08 F6 · kind: On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the "Third Amendment"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration. F6 · price: On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the "Third Amendment"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | OtherConvertible Notes · Derivative | 1,000,000 | Not disclosed Strike: $0.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 5 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 9,500,000 Underlying: Common Stock · 5,405,405 shares Expires 2026-02-01 F6 · kind: On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the "Third Amendment"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration. F6 · price: On March 8, 2024, the Issuer, IntelGenX Corp. and ATAI AG entered into the Third Amended and Restated Loan Agreement (the "Third Amendment"), pursuant to which ATAI AG provided to IntelGenX Corp. an additional term loan in an amount equal to $1,000,000, which is convertible to shares of Common Stock at a price of $0.185 per share. Concurrently and in connection with the execution of the Third Amendment, the Issuer issued to ATAI AG 4,000,000 warrants to purchase shares of Common Stock at an exercise price of $0.17 per share, for no additional consideration. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| November 28, 2023 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | PurchaseWarrant (Right to Buy) · Derivative | 4,053,750 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 4 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 16,052,850 Underlying: Common Stock · 4,053,750 shares Expires 2026-08-31 F5 · price: On November 28, 2023, ATAI AG purchased 750 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $750,000. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| November 28, 2023 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | PurchaseConvertible Promissory Note · Derivative | 750,000 | Not disclosed Strike: $0.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 3 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 2,970,000 Underlying: Common Stock · 4,054,054 shares Expires 2026-08-31 F5 · price: On November 28, 2023, ATAI AG purchased 750 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $750,000. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| October 06, 2023 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | OtherConvertible Notes · Derivative | 8,500,000 | Not disclosed Strike: $0.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 2 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 8,500,000 Underlying: Common Stock · 56,435,098 shares Expires 2025-01-05 F4 · kind: On September 30, 2023, the Issuer, IntelGenX Corp. and ATAI Life Sciences AG ("ATAI AG") entered into the Second Amended and Restated Loan Agreement, which provided, among other things, for the ability for ATAI AG to convert the $8,500,000 principal amount and accrued interest under the original term loan agreement into up to 56,435,098 shares of Common Stock at a price of $0.185 per share, subject to stock exchange approval, which was obtained on October 6, 2023. F4 · price: On September 30, 2023, the Issuer, IntelGenX Corp. and ATAI Life Sciences AG ("ATAI AG") entered into the Second Amended and Restated Loan Agreement, which provided, among other things, for the ability for ATAI AG to convert the $8,500,000 principal amount and accrued interest under the original term loan agreement into up to 56,435,098 shares of Common Stock at a price of $0.185 per share, subject to stock exchange approval, which was obtained on October 6, 2023. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| September 30, 2023 Filed Mar 12, 2024 21:36 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | OtherCall Option (Right to Buy) · Derivative | 7,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-030437 · ownership.xml · derivative · entry 1 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 7,401 Underlying: Units · 7,401 shares Expires 2026-08-31 F1 · derivative.exercise_price: Each unit consists of (a) one $1,000 principal amount convertible promissory note, convertible into shares of Common Stock at $0.185, and (b) 5,405 common stock purchase warrants, at a price of $0.26 per share, at any time prior to August 31, 2026. F2 · kind: On September 30, 2023, ATAI AG entered into an amendment to a subscription agreement with the Issuer to provide ATAI AG with the right to purchase up to 7,401 additional units. F2 · price: On September 30, 2023, ATAI AG entered into an amendment to a subscription agreement with the Issuer to provide ATAI AG with the right to purchase up to 7,401 additional units. F1 · derivative.underlying_shares: Each unit consists of (a) one $1,000 principal amount convertible promissory note, convertible into shares of Common Stock at $0.185, and (b) 5,405 common stock purchase warrants, at a price of $0.26 per share, at any time prior to August 31, 2026. F3 · ownership.nature: Reflects securities held of record by ATAI AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:00 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | PurchaseWarrant (Right to Buy) · Derivative | 11,999,100 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0000950170-23-046540 · ownership.xml · derivative · entry 2 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: 11,999,100 Underlying: Common Stock · 11,999,100 shares Expires 2026-08-31 F2 · price: On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000. F1 · derivative.exercise_date: Each of the convertible promissory notes and the warrants are convertible and exercisable, respectively, at the option of the holder, subject to the shareholder approval limitations, as described further in the respective documents. F3 · ownership.nature: Reflects securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 21:00 UTC | IntelGenx Technologies Corp. IGXT · Entity 91524 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | Not disclosed Strike: $0.19 | $2,220,000.00 |
DisclosureSEC source: 0000950170-23-046540 · ownership.xml · derivative · entry 1 ATAI Life Sciences N.V. · CIK 0001840904 · 10% owner ATAI Life Sciences AG · CIK 0001776242 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By ATAI Life Sciences AG Disclosed balance after: Not disclosed Underlying: Common Stock · 12,000,000 shares Expires 2026-08-31 F2 · price: On August 31, 2023, ATAI Life Sciences AG purchased 2,220 units from the Issuer, with each unit consisting of (i) $1,000 principal amount convertible promissory note and (ii) 5,405 warrants to purchase shares of Common Stock, for aggregate consideration of $2,220,000. F1 · derivative.exercise_date: Each of the convertible promissory notes and the warrants are convertible and exercisable, respectively, at the option of the holder, subject to the shareholder approval limitations, as described further in the respective documents. F3 · ownership.nature: Reflects securities held of record by ATAI Life Sciences AG, which is a wholly owned subsidiary of ATAI Life Sciences N.V., and as a result, ATAI Life Sciences N.V. may be deemed to share beneficial ownership over the securities reported herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.